anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Alzheimer's dementia (AD) is a disorder of uncertain cause and pathogenesis that primarily affects older adults. It accounts for more than 50 percent of cases of dementia in the elderly and is a leading source of morbidity and mortality in the aging population. The most essential and often earliest symptom is selective memory impairment. While treatments can improve some symptoms, there is no cure or disease-modifying therapy, and the disease inevitably progresses in all patients. The mainstay of management is still symptomatic treatment of behavioral disturbances, environmental manipulations to prevent behavioural disturbances, and counseling with respect to safety issues.

The goal of this project is to determine whether low doses of ionizing radiation (LDIR) from repeat CT scanning improves function, cognition and/or behavior in severe AD. This is based upon the treatments given in 2015 to a patient in hospice in the USA with advanced AD. On July 23, she received two CT scans of her brain. Two weeks later she received a third CT scan, and two weeks after this, a fourth CT scan. She partially improved and was discharged to an Alzheimer care home.

In terms of the mechanism whereby CT scanning might lead to improvement, reactive oxygen species (ROS) are produced abundantly and constantly by aerobic metabolism in all organisms, damaging biomolecules including those in the brain. AD is postulated to be caused by the accumulation of oxidative stress damage in the brain that was not prevented, repaired or removed by the patient's own biological protective mechanisms. These systems, characterized genetically, operate against all toxins regardless of whether they are produced endogenously or by external physical, chemical or biological agents. As people age, their protection systems become progressively weaker. LDIR is postulated to stimulate adaptive protection systems. This may produce beneficial effects including improvement in AD symptoms. With about three-quarters of human tissue being water, most of the initial radiation-induced damage is radiolysis of water, producing ROS and hydrogen peroxide (H2O2). LDIR leads to mild oxidative stress and strong signaling, which up-regulates protection.The degree of stimulation likely depends upon individual genetic factors.

CT scans are approved for clinical diagnostic imaging. Approval will be requested from the Research Ethics Board (REB) at Baycrest Health Sciences and from Health Canada to use CT scanning for the experimental treatment of AD. If this pilot study is successful, i.e., if improvement is observed in the participants, then a proposal will be prepared for more comprehensive clinical studies of this novel treatment.
Techniques for improving the accuracy of medical reports prepared by medical professionals. One technique may entail providing a system to automatically pre-populate a medical report by extracting data from a medical imaging study and pre-populating fields in the report with the extracted data. Another technique may entail providing a system to analyze data values from an imaging study during preparation of a medical report, and to generate alerts if at least one analyzed data value is outside of a normal range. The data extracted for pre-populating and/or the data values analyzed for alert generation may correspond to measurement data and/or calculation data from the imaging study. After pre-populating and/or generating alerts in the medical report, the system may present the report to a medical professional to include his/her impressions of the imaging study. Such techniques may enable medical professionals to more accurately and efficiently prepare medical reports for patients.
PURPOSE: To provide an antitumor chromophore having higher antitumor activity obtd. from kedarcidin antibiotic. CONSTITUTION: An aq. soln. of kedarcidin is extracted with ethylacetate, and the extract is subjected to silica gel column chromatograph which uses benzene. methanol process gradient eluting liquid to collect a fraction including the kedarcidin chromophore. The obtd. kedarcidin chromophore C53 H60 N3 O16 Cl is a dull yellow amorphous solid and has IR absorption spectrum in the figure. The chromophore shows 0.29 Rf value (benzene.methanol 9:2 v/v) and 0.16 Rf value (benzene.methanol 9:1 v/v) by silica gel thin layer chromatography and shows 12 minutes high performance liquid chromatograph retention time in a C18 reverse phase silica gel column with tetrahydrofuran-0.2 M ammonium acetate solvent.
Standard 8-week pulmonary rehabilitation programme with 2 supervised sessions per week. In addition they will receive a pedometer with a daily step count target set by a physiotherapist and a written home exercise plan/diary.
Participants are switched from their current opioid medication (oxycodone or morphine) to methadone. Participants receive oral methadone 2-3 times daily for 4 weeks.
NEW MATERIAL:The compound of formula I (n is 6-12). EXAMPLE:1,3-Bis(2,4-octadecadienoyl)-glycero-3-phosphocholine. USE:A compound for forming microcapsule for encapsulating pharmaceuticals, enzymes, photo-sensitive materials for photography, pigments, etc. PREPARATION:For example, the fatty acid of formula II is added with 2-30 times mol of oxalyl chloride and made to react with each other at 50-70 deg.C for 1-3hr to obtain the corresponding acid chloride of formula III. The chloride is reacted with glycerol preferably in an anhydrous solvent (e.g. dichloromethane) containing a dehydrochlorination agent such as quinoline at 10-15 deg.C for 3-24hr to obtain the compound of formula IV, which is made to react with the compound of formula V in the presence of triethylamine, etc.
The application discloses a weever iridovirus MCP2 protein and an expression gene and application thereof. The MCP2-opti recombinant protein is obtained by carrying out codon optimization on the MCP2 recombinant protein, the amino acid sequence of the MCP2-opti recombinant protein is shown as SEQ ID No. 2, and the nucleotide sequence of the MCP2-opti recombinant protein gene is shown as SEQ ID No. 1. Optimized MCP2-opti gene sequenceHigher CAI value, lower ENC value and GC  3S  The content is higher, which indicates that the optimized MCP2-opti gene has higher expression level, stronger gene preference and higher gene translation accuracy. Experiments show that the host of the MCP2-opti recombinant protein is escherichia coli, and the protein expression quantity is highest when the expression vector is pET-32a. The application has positive significance for popularization and application of the soaking vaccine for fishing.
Avoiding burning of tobacco and production of resultant derivs. which are harmful to health comprises infiltration of nicotine into mucous membranes using nicotine contg. media and perfume ointmentsThe carrier is pref. colourless, retains the aroma of tobacco over a set time and can be administered to the human mucous membranes (e.g. the nose). The medium can be in the form of e.g. ointments, ampoules or tampons and has an action on the mouth and throat mucous membranes. The nicotine can be breathed in using a device that chemically filters to ensure the nicotine is derivative free, and that causes the nicotine to evaporate. The nicotine can be breathed in using a pipe which evaporates the nicotine smoke.
Women assigned to the medial breast tissue arm, will have the area of the breast visually divided into 2 equal parts; medial and lateral. The film will be applied to the medial breast tissue by clinically trained staff on day 1 of radiotherapy, the lateral segment will not be covered. The treatment area is cleaned with mild soap, rinsed with water, and dried. The film is applied, sticky side to the skin, then the paper frame is removed. Multiple sheets of non-overlapping film will be used to adequately cover the treatment area. During course of radiotherapy, new film may be applied by clinically trained staff in the event the film no longer adheres to the skin or comes off. Replacement of the film may be done as often as necessary. If there are signs of infection (e.g. redness, feeling warm or swollen), film can be removed. The film will remain in place until one week following the last day of radiotherapy, where it will be removed by the physician or clinically trained staff.
The invention relates to the veterinary microbiology, namely to the prophylaxis remedies and animal bacterial infections treatment. The purpose of the invention consists in the fact that the Bacillus pulvifaciens ÂĘĎĚÂ-4348 bacteria strain producing proteolytic enzymes and antibiotics, hasr a broad action spectrum that alows to increase the effectiveness of animal bacterial infections treatment and prophylaxis. The strain is deposited with the All-Union Collection of industrial microorganisms under B-4348 number.The strain is used for manufacturing of brisk bacterial preparation utilized for treatment and prophylaxis of purulent-inflammatory processes of different localization. The plvifaciens ÂĘĎĚÂ-4348 strain produces proteolytic enzymes decomposing albumin, hemoglobin, fibrin and antibiotics having a broad action spectrum. To the antibiotic are sensible conditional - pathogenic microorganisms: staphylocossus, streptococcus, coli form bacillus, blue - purulent bacillus, proteu solmonellas, dysenteric bacillus, yeast - like fungi. The saprophyted micro flora growh is not suppressed by them. Furthermore, the antibiotic is fully decomposed very quick (during some hours) that excludes the food allergy formation. The proteolytic enzymes contribute to the feeds assimitation.
In our study, the investigators will randomize TURP patients to standard of care versus a multi-modal protocol. Multi-modal pain control is defined as: "analgesia that combines 2 or more agents that act by different mechanisms to provide analgesia with better pain relief and less opioids". In addition, patients in the intervention arm will receive education regarding pain control and opioid use. The investigators aim to demonstrate non-inferior pain control with this approach. The investigators hope this will inform new guidelines for pain control after TURP, minimize opioid use in this patient population, and educate physicians and patients on providing excellent pain control while minimizing the risks of opioid use. The investigators believe this could ultimately serve as a model for other endoscopic urologic procedures as well.
Patients receive tazemetostat PO BID on days 1-21, pembrolizumab IV over 30 minutes on day 1, and topotecan IV over 30 minutes on days 1-5. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study and may also undergo biopsy and collection of blood on study.
Painful diabetic peripheral neuropathy (PDN) presents a serious health problem in China. SCOPE is a cross-sectional, multi-centers registry study with a target sample size of 1500 patients who are experiencing PDN. The patients are treated following guideline and local practice. Real-world data including demographics, medical histories, VAS, PHQ, GAD -7 and therapies are collected. The primary objective is to analyze the clinical characteristics of PDN. The secondary objectives include anxiety depression distribution and current treatment status.The SCOPE study will help to find actual clinical manifestation and treatment and improve the overall treatment outcome of Chinese patients with PDN.
The investigators will evaluate the usability of the sensors and define what features the application should have and how the data should be presented to the users. Participants (n=up to 10) use the sensors for one week and fill out logbooks for physical activity, sleep and diet. Participants fill questionnaires before and after the usage period, and take part in semi-structured interview.
BACKGROUND: Failure of artemisinin-based combination therapy is increasingly reported in patients with Plasmodium falciparum malaria in sub-Saharan Africa. We aimed to describe the clinical and genomic characteristics of recent cases of P. falciparum malaria failing artemether-lumefantrine in Belgium.
METHODS: Travel-related cases of malaria confirmed at the national reference laboratory of the Institute of Tropical Medicine, Antwerp, Belgium, were reviewed. All cases for which attending clinicians reported persistence (beyond Day 3 post-treatment initiation, i.e. early failure) or recrudescence (from Day 7 to 42, i.e. late failure) of P. falciparum parasites despite adequate drug intake were analysed. Both initial and persistent/recurrent samples were submitted to next generation sequencing to investigate resistance-conferring mutations.
RESULTS: From July 2022 to June 2023, eight P. falciparum cases of failure with artemether-lumefantrine therapy were reported (early failure = 1; late failure = 7). All travellers were returning from sub-Saharan Africa, most (6/8) after a trip to visit friends and relatives. PfKelch13 (PF3D7_1343700) mutations associated with resistance to artemisinin were found in two travellers returning from East Africa, including the validated marker R561H in the patient with early failure and the candidate marker A675V in a patient with late failure. Additional mutations were detected that could contribute to decreased susceptibility to artemisinin in another three cases, lumefantrine in six cases and proguanil in all eight participants. Various regimens were used to treat the persistent/recrudescent cases, with favourable outcome.
CONCLUSION: Within a 12-month period, we investigated eight travellers returning from sub-Saharan Africa with P. falciparum malaria and in whom artemether-lumefantrine failure was documented. Mutations conferring resistance to antimalarials were found in all analysed blood samples, especially against lumefantrine and proguanil, but also artemisinin. There is a pressing need for systematic genomic surveillance of resistance to antimalarials in international travellers with P. falciparum malaria, especially those experiencing treatment failure.
In the 'double-drift' illusion, local motion within a window moving in the periphery of the visual field alters the window's perceived path. The illusion is strong even when the eyes track a target whose motion matches the window so that the stimulus remains stable on the retina. This implies that the illusion involves the integration of retinal signals with non-retinal eye-movement signals. To identify where in the brain this integration occurs, we measured BOLD fMRI responses in visual cortex while subjects experienced the double-drift illusion. We then used a combination of univariate and multivariate decoding analyses to identify (1) which brain areas were sensitive to the illusion and (2) whether these brain areas contained information about the illusory stimulus trajectory. We identified a number of cortical areas that responded more strongly during the illusion than a control condition that was matched for low-level stimulus properties. Only in area hMT+ was it possible to decode the illusory trajectory. We additionally performed a number of important controls that rule out possible low-level confounds. Concurrent eye tracking confirmed that subjects accurately tracked the moving target; we were unable to decode the illusion trajectory using eye position measurements recorded during fMRI scanning, ruling out explanations based on differences in oculomotor behavior. Our results provide evidence for a perceptual representation in human visual cortex that incorporates extraretinal information.
A linker-drug represented by formula (I). In formula (I), C is a conjugating linker, L is a linker unit, D is a drug unit, and n is an integer ranging from 1 to 4. The structure of the conjugating linker is represented by formula (II). In formula (II), X is a leaving group, both of R 1  and R 2  are single bond or -NH- and Z is aryl, substituted aryl, heteroaryl, substituted heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or a combination thereof. The wave line of formula (II) indicates the covalent attachment site to L. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. An antibody-drug conjugate (ADC) is also provided.  
C-(L-D) m (I)
This study was conducted as "test-retest" design and the psychometric properties of 3-m backward walk test were examined in LLA. The Rivermead Mobility Index, 3-m backward walk test, Berg Balance Scale, Timed Up and Go test were applied to the patients. An experienced physiotherapist performed all these tests. In order to measure test-retest reliability, the second evaluations (retest) were carried out by the same physiotherapist two days following the first evaluation (test). A same evaluator collected data in order to avoid the inter-rater variability error rate between the evaluations. The patient was evaluated at one time of the day for test and retest.
HAT1 medicated cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The medicated cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. Treatment will continue daily until next visit. If a lesion disappears, patients will continue applying the cream twice daily to the area.
Increasing antimicrobial resistance due to inappropriate antimicrobial use is a global concern. Multi-disciplinary antimicrobial stewardship teams have become an integral part of the response to this issue. Through prospective review of antibiotic prescriptions and feedback (PRF) to healthcare providers, antimicrobial stewardship has been shown to improve clinical response, reduce adverse effects and mortality. However, this strategy is labor-intensive to implement and skilled healthcare workers are an expensive and scarce resource. Antibiotic computerized decision support systems (CDSS) have been used to facilitate these processes and may circumvent the limitations of lack of manpower. In previous studies, CDSS led to increased susceptibility of Pseudomonas aeruginosa to imipenem and Enterobacteriaceae to gentamicin and ciprofloxacin, and an overall reduction in broad-spectrum antibiotic use. CDSS could improve clinical outcomes. Currently, there are limited studies comparing the combined effects of these two strategies.

At Tan Tock Seng Hospital, a university teaching hospital in Singapore, antimicrobial stewardship has focused on PRF by a multi-disciplinary team since 2009. This team reviews piperacillin-tazobactam and carbapenem orders against hospital antibiotic guidelines from day two of antibiotic prescription. In March 2010, we implemented CDSS triggered at the point of antibiotic ordering and compulsory for the prescriber to review. Prescribers are free to accept or reject the CDSS recommendations. While PRF and CDSS are performed following the same institutional guidelines, there may be differences in physicians' acceptance of recommendations and the accessibility to recommendations between these two interventions. In previous studies, PRF recommendations had an acceptance of 60-70% while compulsory CDSS was 40%. The investigators hypothesized that compulsory CDSS and PRF would improve clinical outcomes compared with voluntary CDSS and PRF, and compulsory CDSS would improve appropriate antibiotic practice and reduce the requirement for subsequent PRF.
It is a kind of to treat burn and scald Chinese medicine and preparation method thereof, it is related to a kind of Chinese prescription medicament and preparation method thereof, Chinese medicine production is simple low in cost, to slight, moderate, severe, extra heavy degree empyrosis wound surface processing very simple, the pain for safely, effectively mitigating patient, shortens the course for the treatment of.Burn and scald Chinese medicine is wherein treated, main material: including old rice, tea oil, wherein old rice is clayed into power, and finished medicines are paste old rice powder and tea oil mixture.The beneficial effect is that: 1. analgesic effect is obvious, general action in ten minutes after applying medicine-feeding；2. good in convergence effect, especially to large area without the symptom more than the skin surface of a wound, diffusate；3. protective layer is made good use of；4. treatment procedure it is simple it is one-stop in place, after the surface of a wound applies medicine-feeding, be not necessarily to midway dressing；After the surface of a wound generates new skin histology, powder can voluntarily fall off；5. the Wound healing time is short；6. scar is few after healing, deep burn is without skin-grafting.
Coronary artery bypass surgery (CABG) is performed each year on over 500,000 patients in the US and almost 30,000 patients in Canada to treat coronary artery disease. However, it is complicated by a significant postoperative risk of neurologic sequelae, including stroke and neurocognitive dysfunction (NCD). Clinically overt stroke, which may be seen in 1-4% of patients, is far less common than NCD, which is reported in approximately 50-75% of patients at discharge, 20-50% at 6 weeks and up to 40% at five years.Human recombinant erythropoietin (rh-Epo) is not only approved in this population for prophylactic use to reduce blood transfusions, but has become an agent of intense interest for neuroprotection as a result of in vitro data, animal experiments, and now, two promising preliminary trials in human patients. There are not, however, any pilot data by which to estimate an appropriate dose or treatment effect of rh-Epo on NCD specifically. It is imperative both to refine estimates of control group incidence rates, treatment effect and test variability in CABG, as well to demonstrate the feasibility and safety of a study protocol, prior to embarking on a larger randomized controlled trial powered with an adequate sample size to investigate the efficacy of rh-Epo in the reduction of peri-operative NCD. We propose a six month prospective study in CABG patients to investigate the feasibility and safety of three prophylactic doses of human recombinant erythropoietin (rh-Epo) in a randomized, placebo controlled study. The four study arms are: placebo, 375 U/kg, 750 U/kg, or 1500 U/kg of human recombinant erythropoietin intravenously divided in three doses, the day before, the day of and the day after surgery. The primary outcomes of this pilot will be study feasibility and patient safety as measured by ICU and Hospital length of stay, 28 day all cause mortality, and incidence of morbidity including pure red cell aplasia (PRCA), stroke, myocardial infarction, re-operation, deep vein thrombosis, and pulmonary thromboembolism. The secondary outcome will be the incidence of neurocognitive dysfunction among the four study arms and between placebo and rh-Epo at any dose. As well, little is known about the pharmacology of rh-Epo in crossing the blood-brain barrier. In those patients receiving a spinal anesthetic in addition to a general anesthetic as part of their normal care, CSF will be analyzed for rh-Epo concentration, and then compared to drug dose and serum level.